Evaluation of nivolumab (nivo) alone and in combination with ipilimumab (ipi) in patients (pts) with advanced (adv) small-cell lung cancer (SCLC): First report of a randomized expansion cohort from the CheckMate 032 trial Meeting Abstract
| Authors: | Atmaca, A.; Hellmann, M. D.; Ott, P. A.; Zugazagoitia, J.; Ready, N.; Hann, C. L.; De Braud, F.; Antonia, S.; Ascierto, P.; Moreno, V.; Salvagni, S.; Taylor, M.; Amin, A.; Camidge, D. R.; Horn, L.; Calvo, E.; Brossart, P.; Jäger, D.; Cai, W.; Fairchild, J.; Callahan, M.; Spigel, D. |
| Abstract Title: | Evaluation of nivolumab (nivo) alone and in combination with ipilimumab (ipi) in patients (pts) with advanced (adv) small-cell lung cancer (SCLC): First report of a randomized expansion cohort from the CheckMate 032 trial |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 40 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2017 Sep 29-Oct 3 |
| Meeting Location: | Stuttgart, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2017-09-01 |
| Start Page: | 219 |
| End Page: | 220 |
| Language: | English |
| ACCESSION: | WOS:000411428400530 |
| PROVIDER: | wos |
| PUBMED: | 28934740 |
| DOI: | 10.1159/000479566 |
| Notes: | Meeting Abstract: V760 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
